基于MRI影像组学-临床列线图无创预测晚期高级别浆液性卵巢癌残留病灶
本研究纳入217例晚期高级别浆液性卵巢癌患者,从T2WI和CE-T1WI提取影像组学特征,采用MF融合法构建影像组学标签,并结合临床-影像特征建立列线图。验证集中列线图预测残留病灶的AUC为0.803,显著优于临床-影像特征(AUC=0.623)和MF影像组学标签(AUC=0.744)。
要点
- MF融合法构建的影像组学标签预测性能优于MV融合法(AUC 0.744 vs 0.650)。
- 影像组学-临床列线图在验证集AUC达0.803,有助于术前无创评估残留病灶。
- 双侧肿瘤患者通过融合方法获得与单侧肿瘤可比的影像组学特征。
核心结论
- 基于MRI的影像组学-临床列线图可无创预测晚期HGSOC患者的残留病灶状态,验证集AUC为0.803。
研究设计与样本
- 回顾性研究纳入2014年1月至2019年6月217例晚期HGSOC患者,随机分为训练集160例和验证集57例。
- 从T2WI和CE-T1WI序列各提取841个影像组学特征,采用MV和MF两种融合方法处理双侧肿瘤。
- 使用mRMR方法和LASSO分类器构建影像组学标签,多变量 logistic 回归建立列线图,在验证集评估性能。
诊断标准与关键数值
- MF影像组学标签预测残留病灶的AUC为0.744,显著优于MV标签的AUC 0.650(p=0.047)。
- 影像组学-临床列线图验证集AUC为0.803,显著高于临床-影像特征(AUC=0.623)和MF影像组学标签(AUC=0.744)。
临床应用与阅片要点
- 术前可结合MRI影像组学特征与临床-影像特征,辅助预测晚期HGSOC患者残留病灶风险。
- 对双侧肿瘤患者,采用MF融合法提取影像组学特征可能更有利于预测。
局限性
- 本研究为单中心回顾性设计,样本量有限,外部验证不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop a preoperative MRI-based radiomic-clinical nomogram for prediction of residual disease (RD) in patients with advanced high-grade serous ovarian carcinoma (HGSOC).
METHODS: In total, 217 patients with advanced HGSOC were enrolled from January 2014 to June 2019 and randomly divided into a training set (n = 160) and a validation set (n = 57). Finally, 841 radiomic features were extracted from each tumor on T2-weighted imaging (T2WI) and contrast-enhanced T1-weighted imaging (CE-T1WI) sequence, respectively. We used two fusion methods, the maximal volume of interest (MV) and the maximal feature value (MF), to fuse the radiomic features of bilateral tumors, so that patients with bilateral tumors have the same kind of radiomic features as patients with unilateral tumors. The radiomic signatures were constructed by using mRMR method and LASSO classifier. Multivariable logistic regression analysis was used to develop a radiomic-clinical nomogram incorporating radiomic signature and conventional clinico-radiological features. The performance of the nomogram was evaluated on the validation set.
RESULTS: In total, 342 tumors from 217 patients were analyzed in this study. The MF-based radiomic signature showed significantly better prediction performance than the MV-based radiomic signature (AUC = 0.744 vs. 0.650, p = 0.047). By incorporating clinico-radiological features and MF-based radiomic signature, radiomic-clinical nomogram showed favorable prediction ability with an AUC of 0.803 in the validation set, which was significantly higher than that of clinico-radiological signature and MF-based radiomic signature (AUC = 0.623, 0.744, respectively).
CONCLUSIONS: The proposed MRI-based radiomic-clinical nomogram provides a promising way to noninvasively predict the RD status.
KEY POINTS: • MRI-based radiomic-clinical nomogram is feasible to noninvasively predict residual disease in patients with advanced HGSOC. • The radiomic signature based on MF showed significantly better prediction performance than that based on MV. • The radiomic-clinical nomogram showed a favorable prediction ability with an AUC of 0.803.
引用
- Li H, Zhang R, Li R, et al. Noninvasive prediction of residual disease for advanced high-grade serous ovarian carcinoma by MRI-based radiomic-clinical nomogram. Eur Radiol. 2021. PMID: 33864139. doi:10.1007/s00330-021-07902-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。